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Abstract  
 
Introduction 
Standards of care are not yet defined in recurrent glioblastoma.  
Methods 
We reviewed the literature on clinical trials for recurrent glioblastoma available in 
PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015.  
Results 
Evidence is limited due to the paucity of randomized controlled studies. Second surgery 
or re-irradiation are options for selected patients. Alkylating chemotherapy such as 
nitrosoureas or temozolomide and the vascular endothelial growth factor (VEGF) 
antibody, bevacizumab, exhibit comparable single agent activity. Phase III data 
exploring the benefit of combining bevacizumab and lomustine are emerging. Novel 
approaches in the fields of targeted therapy, immunotherapy, and tumor metabolism are 
coming forward. Several biomarkers are being explored, but, except for O(6)-
methylguanine DNA methyltransferase (MGMT) promotor methylation, none has 
assumed a role in clinical practice.  
Conclusion 
Proper patient selection, development of predictive biomarkers and randomized 
controlled studies are required to develop evidence-based concepts for recurrent 
glioblastoma. 
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Highlights:  
1. Standards of care are incompletely defined in recurrent glioblastoma. 
2. The evidence for repeat surgery or reirradiation is limited. 
3.  Alkylating chemotherapy (nitrosourea, temozolomide) is a widely accepted 
therapeutic option. 
4.  Bevacizumab has clinical activity, but an effect on overall survival is uncertain. 
5. Individualized treatment concepts should consider age, performance status, 
MGMT promoter methylation status, response to and type of previous regimens and 
quality of life.  
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1. Introduction 
Despite advances in the understanding of its biology, glioblastoma, the most common 
malignant brain tumor, remains a devastating disease. Median overall survival (OS) 
in population-based studies in the US was 8.1 months in the period of 2000 – 2003 
and 9.7 months from 2005 -2008 [1]. In 2005, the current standard of care in newly 
diagnosed glioblastoma was established based on the trial of the European 
Organisation for Research and Treatment of Cancer (EORTC)/National Cancer 
Institute of Canada Clinical Trials Group (NCIC-CTG) showing prolonged median OS 
of 14.6 months by addition of temozolomide (TMZ) during and after radiotherapy 
compared to radiotherapy alone (12.1 months) [2]. Promoter methylation of the O6-
methylguanine-DNA methyltransferase (MGMT) gene was established as a predictive 
biomarker for benefit from TMZ in newly diagnosed glioblastoma [3]. For elderly 
patients, e.g., older than 65-70 years, the standard of care for newly diagnosed 
glioblastoma without MGMT promoter methylation or unknown MGMT status is 
radiotherapy alone [4]. In contrast, elderly patients with glioblastoma with MGMT 
promoter methylation should receive TMZ without or with radiotherapy [5-7].  
Tumor recurrence occurs in almost all patients. Currently, no standard of care is 
established in recurrent or progressive glioblastoma [7]. Despite numerous clinical 
trials, the identification of effective therapies is complicated by the lack of appropriate 
control arms, selection bias, small sample sizes and disease heterogeneity [8].  
 
2. Scope and objectives 
Here we review clinical efficacy data for the treatment of patients with recurrent 
(=progressive) glioblastoma with focus on prospective and randomized clinical trials 
published in PubMed or as ASCO abstract reports until June 2015. Phase I or 
retrospective studies were only included in case of lack of prospective data, or for 
historical or innovative importance. We discuss the current status of diagnosis of 
tumor response and progression. The therapeutic value of repeat surgery and 
radiotherapy as well of different systemic treatment regimens including nitrosoureas, 
temozolomide, bevacizumab, targeted therapies, combinational approaches or novel 
concepts including immunotherapy in patients with recurrent glioblastoma are 
reviewed, with a focus on new data emerging since 2013 [8]. Finally, the impact of 
these clinical trials on current clinical practice in recurrent glioblastoma is discussed.  
 
3. Results 
3.1 Diagnosis of progression and response 
Criteria for response and progression in glioblastoma have remained a matter of 
debate for the past decades. Still, MRI imaging every 2 to 3 months remains the gold 
standard for diagnosis of response or progression in glioblastoma. However, several 
concerns have been raised regarding the Macdonald criteria, being the standard tool 
for response evaluation until 2010 [9]. Limitations included the observation of 
“pseudoprogression” as a transient increase of contrast-enhancing tumor especially 
within the first 3 months after completion of radiotherapy as well as 
“pseudoresponses“ with divergent effects on contrast-enhanced T1-images versus 
T2/fluid-attenuated inversion recovery (FLAIR) sequences especially with use of 
antiangiogenic agents. Since 2010, the updated criteria for Response Assessment in 
Neuro-Oncology (RANO) add restricted parameters for diagnosis of progressive 
disease within 3 months after completion of radiochemotherapy and integrate the 
evaluation of T2/FLAIR sequences as well of corticosteroid use [10]. Recently, the 
same group has provided an international consensus protocol based on the 
development of the EORTC Brain Tumor Group for uniform evaluation in clinical trials 
and practice [11]. Comparing overall response rates and progression-free survival 
(PFS) in different clinical trials using either Macdonald or RANO criteria is thus 
difficult. To date, the RANO criteria are considered the best standardized tool for 
evaluation of response and progression in glioblastoma. Several imaging techniques 
and modalities have been proposed for the identification of response or progression 
as well as prognostic or predictive tools for therapeutic efficacy, e.g. perfusion 
imaging, dynamic susceptibility contrast, apparent diffusion coefficient and MR 
spectroscopy [12-18]. However, these studies are limited in patient size and/or 
adequate control groups. To date, in case of suspected pseudoprogression, repeated 
MRI imaging in shortened time intervals is recommended, while usually maintaining 
treatment. O-(2-(18)F-fluoroethyl)-L-tyrosine)-positron emission tomography ((18)F-
FET-PET) may help to identify pseudoprogression versus early progression after 
radiochemotherapy, too [19].  
3.2 Surgery at recurrence 
The role of repeat surgery in patients with progressive or recurrent glioblastoma 
remains controversial. Some retrospective studies proposed a survival benefit after 
reoperation [20-23] while others did not [24]. Limitations of most of the studies 
include high probability of selection bias and lack reasonable controls for comparison 
[25]. Factors proposed for benefit of surgery and decision-making represent general 
prognostic factors for glioblastoma, such as age, MGMT promotor methylation, 
performance status, tumor volume, extent of resection, and tumor localization. A 
scale including tumor involvement in non-eloquent areas, small tumor volume (< 50 
cm3) and good performance status (KPS>80%) was proposed in 2010 and modified 
to a score comprising KPS and ependymal involvement for decision making 
regarding reoperation, based on retrospective data [26, 27].  
Few prospective data sets on repeat surgery are available. A prospective registry 
study of 764 patients with glioblastoma analyzed over a 7-year period (2004-2010) 
with one third of patients reoperated at recurrence did not suggest a benefit of repeat 
surgery (HR 1.02), however, no detailed patient stratification for prognostic variables 
was available [28]. Similarly, in a meta-analysis of 8 prospective phase I and II trials 
comprising 300 patients with recurrent glioblastoma repeat surgery was not an 
independent predictor for PFS and OS [29]. A post-hoc analysis of the prospective 
DIRECTOR trial evaluating two different dosing schemes of TMZ in patients with 
recurrent glioblastoma did not show a difference in overall survival in patients with 
(n=71) versus without (n=34) surgery at recurrence. However, when stratifying for 
extent of resection (n=59 available for analysis), there was superior survival in 
patients with complete resection of gadolinium-enhancing tumor (n=39) [30]. 
Similarly, a prospective non-randomized registry for patients with repeat surgery 
identified a correlation between (high) extent of resection and survival [31].  
Beyond an expected therapeutic efficacy of repeat surgery, the acquisition of tumor 
tissue at recurrence might be valuable in some situations, e.g. for diagnosis of 
recurrent disease (e.g. versus radiation necrosis), confirmation of initial histology 
and/or determination of molecular markers for biomarker-based decision making.  
 
3.3 Repeat radiotherapy 
Re-irradiation is a similarly controversial option for patients with recurrent 
glioblastoma. Evidence-based clinical decision making is impeded by the lack of 
prospective and randomized trial design and high probability of selection bias in 
single arm studies. Main concerns include safety with regard to radiation necrosis 
and neurocognitive impairment as well as limited efficacy at recurrence after initial 
irradiation. Without establishment in prospective or controlled studies, for fractionated 
stereotactic radiotherapy total doses between 30-36 Gy in 2-3.5 Gy fractions with or 
without intensity modulation have been used [32, 33]. Radiosurgery is less frequently 
used in glioblastoma. As favorable variables for selecting patients likely to benefit 
from re-irradiation again general prognostic factors such as young age, high KPS or 
small tumor size have been proposed [32, 34-37]. Different reports exist regarding 
the preferred time interval to initial radiation for benefit from re-irradiation, favoring 
either an interval of less than 6 months [35] or more than 6 or even 12 months [37, 
38]. 
Several combination partners have been proposed for re-irradiation with the 
hypothesis of synergistic effects. A randomized phase II study evaluating re-
irradiation with and without the addition of a CD95 ligand-binding fusion protein, 
APG101, showed poor outcome in the re-irradiation-only arm (PFS-6 3.8%, median 
PFS 2.5 months) but significantly higher PFS-6 (20.7%) and median PFS (4.5 
months) in the combination arm. However, median OS was equal in both groups with 
11.5 months. Presence of CD95L as determined by promoter methylation may 
identify patients benefitting from APG101 [39]. Several studies evaluated the 
combination of bevacizumab with re-irradiation with the hypothesis that vascular 
normalization results in improved oxygenation of tumor tissue and thereby increases 
the effect of radiation. With heterogeneous cohorts of WHO grade III (n=6, n=14, 
n=12) and glioblastomas (n=8, n=43, n=42) treated with re-irradiation with and 
without bevacizumab a higher median PFS (5.7 vs. 3.7, 5.6 vs. 2.5, and 6 vs. 4 
months) and higher median OS (8.3 vs. 14.3, 8.6 vs. 5.7, 11 vs 8.3 months) were 
reached in 2 of 3 retrospective studies in the bevacizumab cohort [40-42]. In the 
study of Minniti and colleagues the non-bevacizumab group received fotemustine. A 
prospective study evaluating stereotactic radiosurgery plus bevacizumab (n=8 
patients with anaplastic glioma, n=7 with glioblastoma) reported a median PFS of3.9 
and median OS 14.4 months. Toxicity included one grade 3 and two grade 2 CNS 
toxicities [43].  
 
3.4 Chemotherapy for recurrent glioblastoma 
The landscape of chemotherapeutic trials in recurrent glioblastoma is influenced by 
the historical evolution of the standard of care for newly diagnosed and recurrent 
disease, heterogeneity of inclusion criteria, choice of endpoints and response criteria, 
pretreatment and patient characteristics. In addition, most studies are non-
comparative or fail to use a control arm lacking the experimental drug.  
Some, especially older trials include both anaplastic gliomas and glioblastoma. Trials 
conducted before the establishment of standard TMZ-based radiochemotherapy in 
2005 commonly included TMZ-naïve patients. Different endpoints and use of different 
response criteria further impede comparability of trials. Six-months PFS rate (PFS-6) 
and median OS from the time of treatment for recurrence are reasonable endpoints 
for clinical trials in recurrent glioblastoma [44], however, criteria of response and 
progression are still moving targets.   
 
3.4.1 Nitrosourea monotherapy and combination regimens 
Nitrosoureas (e.g., carmustine [BCNU], lomustine [CCNU], nimustine [ACNU], 
fotemustine) are DNA alkylating agents that cross the blood-brain barrier and have 
been extensively used in glioma treatment. They may induce considerable 
hematological toxicity with long-lasting bone marrow suppression, liver and renal 
toxicity, and, specifically carmustine, interstitial lung disease. After approval of TMZ in 
1999 for recurrent glioblastoma based on efficacy data of 2 phase II trials and a 
favorable safety profile [45, 46], nitrosoureas were used less frequently. Their use 
rose again when TMZ became standard of care in newly diagnosed glioblastoma. 
Table 1 summarizes nitrosourea-based trials in recurrent glioblastoma. There are 5 
single arm phase II trials with nitrosourea monotherapy (1 with carmustine, 4 with 
fotemustine at different dosing regimens) [47-51] and 6 randomized phase II or 
phase III trials comprising one therapeutic arm with nitrosourea monotherapy: 5 trials 
with lomustine [52-56] and 1 trial with carmustine where data for patients treated with 
carmustine (n=29) were not separately reported but summarized in a common 
“control” arm with 27 patients receiving TMZ [57]. All but 3 trials were conducted at 
the first recurrence after TMZ-based standard radiochemotherapy. One study was 
done in chemotherapy-naïve-patients [47], one study did not disclose previous 
chemotherapy except exclusion of nitrosourea, bevacizumab or investigational 
agents [53], one study reported previous chemotherapy in about 60% of the patients 
without details [57]. PFS-6 ranged between 17.5% and 61.5% and median OS 
between 6.0 and 11.1 months for monotherapy of nitrosourea agents.  
Notably, in the randomized studies, lomustine as monotherapy showed comparable 
results with the investigational agents enzastaurin, cediranib, galunisertib or 
bevacizumab [52-55], pointing towards relevant single agent activity of the “control” 
agent or lack of efficacy of the experimental agents The combination of lomustine 
plus bevacizumab showed prolonged median PFS and OS and higher PFS-6 than 
the single agents in the BELOB phase II trial [54]. However, the combination 
treatment at least with the higher dose of lomustine with 110 mg/m2 exhibited more 
hematological toxicity leading to the dose reduction to 90 mg/m2 when combined with 
bevacizumab. Another randomized phase II trial evaluated the combination of 
lomustine with 90 mg/m2 with bevacizumab 5 mg/kg every 3 weeks versus 
bevacizumab alone at 10 mg/kg every 2 weeks in a heterogenous cohort of patients 
with glioblastoma at 1st, 2nd or 3rd relapse. The authors emphasized a benefit for the 
subgroup of patients at 1st relapse in the combination arm with a median OS with 
13.1 months versus 8.8 months in the monotherapy arm without disclosing the 
number of patients in this subgroup and without reporting PFS and OS results of the 
intent-to-treat population [58]. Another phase II study evaluated the combination of 
nitrosourea, namely fotemustine with bevacizumab, however, not in a randomized but 
single-arm design [59]. PFS-6-rate of 42.6% was similar with the BELOB trial with a 
median OS of 9.1 months (BELOB: 11 months [54]). Again, hematological toxicity 
was relevant with 22% of the patients discontinuing fotemustine due to grade 3 or 4 
myelotoxicity. The promising efficacy signal of the combination of nitrosoureas with 
bevacizumab of phase II trials was not confirmed in the EORTC 26101 phase III trial 
comparing lomustine plus bevacizumab with lomustine alone in patients with 
recurrent glioblastoma which did not report a difference in OS (8.6 versus 9.1 
months), although prolonged PFS (1.5 versus 4.2 months) was confirmed [56].  
Other studies regarding nitrosourea combination therapies for recurrent disease are 
mostly retrospective. One phase II trial evaluating the combination of carmustine and 
irinotecan showed PFS-6 of 30.3%, median PFS of 3.9 and median OS of 11.7 
months. Beyond hematologic toxicities, mainly grade 1 and 2, frequent diarrhea (69% 
grade 1 and 2, 7.1% grade 3) and 9.5% cholinergic syndrome were seen [60]. The 
combination of TMZ with nitrosoureas, fotemustine or carmustine, was evaluated in 2 
prospective studies, both with severe and frequent hematologic toxicities leading to 
dose reductions and early stop of enrolment in one study without clear efficacy 
signals beyond single agent activity [61, 62].  
In summary, the different nitrosoureas show probably comparable efficacy as single 
agents and remain to be one standard of care at least for current clinical trials. It is 
likely to expect that clinical efficacy will be more prominent in patients with tumors 
with MGMT promoter methylation [54, 63]. The substantial toxicity profile limits 
combination with other agents. 
 
3.4.2 Temozolomide monotherapy and combination regimens 
Table 2 provides an overview on clinical trials of TMZ monotherapy, randomized trials 
with a TMZ monotherapy arm and combination regimens. TMZ was approved in 1999 
for recurrent glioblastoma based on the data of 2 phase II trials.  
TMZ was superior to procarbazine in patients, 60% of which were pretreated with 
nitrosoureas, with a PFS-6 rate of 21% vs. 8% and median OS prolonged by 1.5 
months [46]. A single-arm phase II trial in 126 patients led to a PFS-6 rate of 18% 
[45]. Both trials used a schedule of TMZ 150-200 mg/m2 for 5 out of 28 days. Other 
prospective studies mainly without previous TMZ treatment using this schedule 
showed similar PFS-6 rates ranging from 21 to 24% [64-67].  
Alternative schedules of TMZ were developed aiming at overcoming TMZ resistance 
or exerting additional biologic effects, e.g. on angiogenesis. The main alternative 
schedules (Table 2) comprise low dose daily TMZ (40-50 mg/m2/d), 1-week-on/1-
week-off (150 mg/m2 for 7 days every 14 days), and 3-week-on/1-week-off (75-100 
mg/m2 for 21 days every 28 days). Grade 3 and grade 4 hematologic toxicities were 
observed in most of the studies without apparent differences between the schedules. 
Since most of the studies were conducted as single-arm monotherapy trials with 
different inclusion criteria e.g. regarding number of recurrences and pretreatment 
characteristics, comparison of efficacy outcome is limited. Yet, it seems very unlikely 
that there are relevant differences between the various dose-intensified TMZ 
regimens, and their superiority over standard dose TMZ for patients experiencing 
recurrence after a TMZ-free interval has not been demonstrated either. The RESCUE 
phase II trial evaluated the timing of TMZ rechallenge with prospective grouping of 
patients. Patients who received continuous TMZ for progression during the first 6 
cycles of adjuvant TMZ and those patients with a treatment-free interval longer than 2 
months showed comparable PFS-6 rates of 27.3 and 35.7% (median PFS 3.6 and 
3.7 months) deriving more benefit than those patients receiving TMZ beyond the 
standard 6 adjuvant cycles but without a treatment-free interval (PFS-6 7.4%, median 
PFS 1.8 months) [68].  
Beyond the randomized trial leading to the approval of TMZ mentioned above, two 
other randomized trials with TMZ monotherapy as one of the treatment arms have 
been published, a direct comparison with the combination of procarbazine, lomustine 
and vincristine (PCV) before TMZ became first-line standard [69] and a negative trial 
for the epidermal growth factor recetor (EGFR) tyrosine kinase inhibitor afatinib [70] 
(Table 2 and 4), indirectly supporting the role of TMZ at recurrence.  
The DIRECTOR trial compared TMZ 120 mg/m2 for 7 days every 14 days with 3-
week-on/1-week-off 80 mg/m2 for 21 days every 28 days and found no difference in 
outcome between these two regimens [71]. However, this trial established the role of 
MGMT promotor methylation as a prognostic marker for benefit of TMZ in recurrent 
glioblastoma patients, with a PFS-6 of 39.7% in patients with MGMT promoter-
methylated tumors versus 6.9% without MGMT promoter methylation, in a 
prospective manner. The benefit of TMZ at recurrence thus seems limited to patients 
with tumors with MGMT promoter methylation. 
Numerous studies evaluated TMZ-based combination regimens in recurrent 
glioblastoma. Beyond the combination with nitrosoureas already discussed, the 
following combination partners have been prospectively evaluated in single-arm 
designs: 
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab [72-75], 
interferon-α2b [76], the multikinase inhibitor sorafenib [77], O6-benzylguanine [78], 
irinotecan [79], cisplatin [80, 81], liposomal doxorubicine [82] and ABT-414, an 
EGFR-targeted antibody-drug conjugate conjugated to monomethylauristatin F [83]. 
So far, these trials have failed to provide convincing efficacy signals beyond single 
agent activity of TMZ. 
 
3.4.3 Other classical non-alkylating chemotherapy 
Beyond chemotherapy with alkylating agents (TMZ or nitrosoureas), other classical 
non-alkylating chemotherapeutics have been explored in the treatment of recurrent 
glioblastoma. A detailed listing of all trials with these agents, mostly conducted as 
single arm studies, would be beyond the scope of this review. Carboplatin 
(CABARET trial) and irinotecan (BRAIN trial) have been evaluated in randomized 
phase II trials as add-ons to bevacizumab (Table 3) [84, 85]. Both trials were 
negative showing no difference in outcome but additional toxicity in the treatment 
arms with carboplatin and irinotecan. 
 
3.4.4 Bevacizumab monotherapy and combination regimens 
Table 3 summarizes trials with single-arm monotherapy, randomized trials and single 
arm combination containing bevacizumab. Bevacizumab was approved in 2009 for 
the treatment of recurrent glioblastoma by the FDA and in several other countries 
based on the results of 2 uncontrolled phase II trials with overall response rates of 
about one third of the patients and with PFS-6 rates of 42.6 and 29% [85, 86]. In 
Europe, approval was refused because of the lack of a bevacizumab-free control 
arm. There are 9 phase II trials with a bevacizumab monotherapy arm, 3 of them 
single-arm studies [86-88], 5 trials compared bevacizumab with bevacizumab plus 
another agent, such as irinotecan [85], carboplatin [84], the histone-deacetylase 
inhibitor vorinostat [89], the multikinase inhibitor dasatinib [90] or lomustine [58]. Only 
one trial had a bevacizumab-free control arm with lomustine [54]. Most of these trials 
used bevacizumab at 10 mg/kg IV every 2 weeks except one study with 15 mg/kg IV 
every 3 weeks [87] and one study with 5 mg/kg IV every 3 weeks when combined 
with lomustine [58]. Toxicity of bevacizumab was mainly non-hematologic including 
hypertension, thrombembolic events, fatigue, and impaired wound healing. Overall 
response rates were similar in most trials with around one third of the patients mainly 
assessed by Macdonald criteria but also by RANO [54, 90], while one trial only 
reports 6%, assessed by RANO criteria [84]. PFS-6 rates ranged from 18% to 42.6% 
and median OS from 6.5 to 9.2 months. In the randomized trials adding another 
experimental agent to bevacizumab (irinotecan, carboplatin, vorinostat or dasatinib) 
versus bevacizumab alone, both arms showed comparable efficacy leading to the 
conclusion of poor efficacy of the experimental agent without valid evidence 
regarding the single agent activity of bevacizumab [84, 85, 89, 90]. The BELOB trial 
comprising a bevacizumab-free control arm showed comparable single agent activity 
of bevacizumab versus lomustine. However, as already discussed, median OS of the 
combination of bevacizumab and lomustine was superior to single agent activity in 
this phase II trial in contrast to the EORTC 26101 phase III trial showing no difference 
in OS of the combination versus lomustine alone [54, 56]. 
More than one dozen prospective trials evaluated bevacizumab in combination with 
other experimental agents in a single-arm design (Table 3). The trials combining 
bevacizumab with nitrosoureas or TMZ have already been mentioned in Table 1-2. 
Surprisingly, the combination of bevacizumab with TMZ [72-75] seems less promising 
than the combination with nitrosoureas [54, 58, 59]. However, no direct comparisons 
are available and the trials evaluating bevacizumab plus temozolomide were 
conducted in part in highly pretreated patient populations [72-74]. Five phase II trials 
evaluated the combination of irinotecan with bevacizumab [91-95], two trials added a 
third combination partner, cetuximab [96] or carboplatin [97]. PFS-6 rates ranged 
between 28 and 50.3% and median OS between 6.7 and 9.7 months. Other 
experimental agents that were combined with bevacizumab are etoposide [98], the 
mTOR inhibitor temsirolimus [99], the EGFR-targeted tyrosine kinase inhibitor 
erlotinib [100], the multikinase inhibitor sorafenib [101], the histone deacetylase 
inhibitors panobinostat [102] or vorinostat [103].  
No efficacy signal beyond the data for bevacizumab monotherapy was seen except 
for lomustine at phase II with negative results in the comparative phase III trial 
(EORTC 26101) [54, 56]; in addition, some of the combination trials reported 
increased toxicity. 
In the clinic, after progression on a bevacizumab-containing regimen, bevacizumab is 
often continued fearing a rebound effect when stopping antiangiogenic therapy and 
data from metastatic colorectal cancer support this concept [104]. This clinical 
practice so far was lacking evidence from prospective and controlled clinical trials. 
This question was prospectively addressed with the cohort of the CABARET 
randomized phase II trial comparing bevacizumab monotherapy with bevacizumab 
plus carboplatin [105]. Upon progression of one of the two regimens, patients were 
randomized again to continue or cease bevacizumab. Patients previously receiving 
bevacizumab monotherapy could receive carboplatin or supportive care and those 
treated with combined bevacizumab plus carboplatin ceased carboplatin and could 
receive TMZ, etoposide or supportive care according to clinician choice. Forty-eight 
of initially 120 patients (40%) were available for randomization. There were no 
differences in outcome with a poor overall response of 0% in both arms, median PFS 
of the group continuing bevacizumab versus ceasing was 1.8 versus 2.0 months, OS 
was 3.4 versus 3.0 months. 
In conclusion, there is little evidence to continue bevacizumab in patients with 
glioblastoma after progression on a bevacizumab-containing regimen. 
 
3.4.5 Targeted therapy 
In the last decade, a plethora of agents have been suggested for targeting essential 
pathways in glioblastoma. The pharmacologic agents had commonly been tested in 
vitro or in vivo or both before. Table 4 gives an overview on several phase II studies 
conducted with agents targeting receptors or soluble factors involved in 
angiogenesis, oncogenic pathways or factors presumably involved in tumor cell 
stemness or tumor invasiveness. Most studies were designed as single-arm trials, 
some agents were tested in a randomized fashion against lomustine or TMZ. The 
results of single-arm phase II studies again are likely to be influenced by selection 
bias, patient heterogeneity and small patient numbers. Those agents tested against 
lomustine or TMZ failed to prove superiority.  
Candidate anti-angiogenic agents other than bevacizumab, e.g. aflibercept, sunitinib, 
vandetanib or nintedanib failed to give an efficacy signal. Cediranib, a pan-tyrosine 
kinase inhibitor of VEGFR achieved similar response rates and PFS-6-data as did 
bevacizumab in phase II [85, 86, 106]. The subsequent phase III trial of cediranib 
showed comparable but not better efficacy than lomustine. Still, it is surprising that 
cediranib which is supposed to be similarily active as bevacizumab did not show 
superiority in combination with lomustine [52]. Further, the clinical development of a 
placental derived growth factor antibody was stopped early for presumed lack of 
activity [107]. 
Targeted agents aiming to inhibit oncogenic pathways such as enzastaurin, 
everolimus, PX-866, selinexor or dasatinib showed disappointing results [53, 108-
111]. The phase II trial evaluating the multikinase inhibitor dasatinib only included 
patients with activation or overexpression of ≥2 putative dasatinib targets (ie, SRC, c-
KIT, EPHA2, and PDGFR), nevertheless with poor efficacy results [111]. A placebo-
controlled randomized phase II trial evaluating galunisertib, an inhibitor of 
transforming growth factor (TGF)-β receptor-1, shown to be involved in multiple 
pathogenic processes in glioblastoma in vitro, did not improve outcome when 
combined with lomustine [55]. However, the trial design containing a placebo-
controlled active control (lomustine+placebo) at least allows reasonable conclusions 
on activity. The integrin inhibitor cilengitide tested in two dosing regimens in a 
randomized fashion, without a control arm lacking the experimental agent, showed a 
trend to prolonged survival at the higher dose [112]. A novel principle, the inhibition of 
histone deacetylase aiming to target epigenetic gene regulation, with agents such as 
vorinostat or panobinostat so far failed to provide efficacy signals [89, 102, 113, 114]. 
However, based on the mechanism, the combination with cytoxic drugs such as 
lomustine or temozolomide might rather lead to synergistic effects than with 
bevacizumab. Several EGFR-targeting agents have been developed, such as 
gefitinib, erlotinib or afatinib, a strategy effective in EGFR-mutated non-small-cell lung 
cancer, however, so far with disappointing results in glioblastoma [57, 70, 108, 115]. 
The phase II trial evaluating afatinib, an irreversible ErbB family blocker, showed that 
in the biomarker cohort (70 patients, 59%) the median PFS in those patients treated 
with afatinib monotherapy with EFGRvIII-positive tumors vs -negative tumors was 3.4 
vs 1.0 months pointing towards efficacy in subgroups (over-)expressing the target 
[70]. The efficacy of ABT-414 might be further improved in a target-selected cohort 
since all patients of an unselected phase I cohort with confirmed response had EGFR 
amplification [83]. A current phase II trial (Clinicaltrials.gov NCT02343406) 
investigates whether ABT 414 alone or combined with temozolomide is superior to 
lomustine or temozolomide re-challenge in recurrent EGFR-amplified glioblastoma. In 
conclusion, so far none of the targeted agents has proven efficacy beyond the activity 
of alkylator therapy. 
In conclusion, so far none of the targeted agents has proven efficacy beyond the 
activity of alkylator therapy. 
 
3.4.6 Immunotherapeutic approaches 
Therapeutic principles of immunotherapy include immunomodulatory drugs aiming at 
activating the immune system against the tumor, treatment with oncolytic viruses and 
different vaccination approaches, either cell-based or antigen-based or both. All 
approaches theoretically should work best if applied early in the course of the 
disease to patients with minimal residual disease. This is why the majority of 
immunotherapeutic studies in glioblastoma today are conducted in the first-line 
setting and no longer in recurrent glioblastoma.  
A promising immunotherapeutic approach is “immune checkpoint inhibition” 
interfering with inhibitory T cell signaling via programmed death 1 (PD-1), the PD-1-
ligand, or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Preliminary data of 
a phase II study, randomizing patients with recurrent glioblastoma to either 
nivolumab, a PD-1 antibody, alone or combined with ipilimumab, a CTLA-4 antibody, 
showed an overall survival rate of 75% at 6 months for both arms pooled [116]. 
Relevant toxicity including included colitis, cholecystitis, diabetic ketoacidosis, and 
confusion leading to discontinuation occurred in the combination arm in 50% of the 
patients. Other checkpoint inhibitors targeting PD-1 (Pembrolizumab, 
Clinicaltrials.gov NCT02337491) or PD-L1 (MEDI4736, Clinicaltrials.gov 
NCT02336165) are currently evaluated in phase II.   
A phase I trial in recurrent glioblastoma evaluated TMZ combined with a vaccine of 
monocyte-derived dendritic cells pulsed with autologous tumor cells previously been 
exposed to TMZ. Two of 9 patients had objective radiological responses and were 
progression-free at 6 months [117].  
Gliovac, a vaccine composed of autologous and allogene antigens combined with 
GM-CSF and previous treatment with cyclophosphamide was shown to be safe in 
phase I and all patients (n=9) were alive at 6 months [118]. A phase II trial (n=41 
patients) evaluated a vaccine composed of heat shock peptide protein complexes 
(HSPPC-96) after repeat tumor resection. PFS-6 of evaluable patients was 29.3%, 
median PFS 4.4 and median OS 9.8 months [119]. Strict patient selection after 
inclusion for being “evaluable” (30% were excluded) limits the interpretation of these 
results. A phase II trial showed promising results for rindopepimut, a vaccine 
consisting of a peptide sequence of EGFRvIII, plus bevacizumab versus 
bevacizumab plus control vaccine in bevacizumab-naïve patients (1st or 2nd relapse, 
n=72). The rindopepimut arm had higher overall response rate (24% vs. 17%), 
prolonged PFS-6 (27% vs. 11%) and median OS (12 vs. 8.8 months). An association 
of an anti-EGFRvIII immune titer generation with OS within the rindopepimut arm 
further supports this approach [120].  
 
3.4.7 Other approaches 
Beyond repeat surgery, irradiation, various chemotherapic and immunotherapeutic 
approaches, two further treatment concepts for recurrent glioblastoma shall be briefly 
mentioned. One approach comprises a portable device, called tumor-treating 
alternating electric fields (TTFields/NovoTTF), delivering low-intensity, intermediate 
frequency electric fields via non-invasive, transducer arrays aiming at physically 
interfere with cell division. NovoTTF(n=120 patients, 20-24h/d) was evaluated in a 
randomized phase III trial versus best physicians choice of chemotherapy (n=117 
patients: bevacizumab in 31%, irinotecan in 31%, nitrosourea in 25%, carboplatin in 
13%, temozolomide in 11% of patients). Median OS was comparable in both groups 
with 6.1 versus 6.6 months, PFS-6 was 21.4% and 15.1%. Toxicity was limited to 
moderate and mild skin reactions [121]. The interpretation of these data remains 
controversial, but the trial was overall as negative as many other trials discussed 
above.  
Another “chemotherapy-free” approach represents the ERGO trial that examined a 
ketogenic diet in 20 patients with recurrent glioblastoma. With a median PFS of 1.2 
and an OS of 7.4 months, there was no evidence of activity [122].  
 
4. Summary and conclusion 
Despite a plethora of clinical trials in recurrent glioblastoma, there are no established 
standards of care beyond alkylating chemotherapy or bevacizumab. The future role 
of bevacizumab is uncertain since the EORTC 26101 trial failed to demonstrate 
superiority for OS of lomustine plus bevacizumab over lomustine alone [56]. Many 
single-arm trials are difficult to interpret because of the lack of a controlled and 
randomized design and heterogeneous cohorts. Stratification of patients according to 
prognostic markers and implementation of control groups already in phase II trials 
may improve design and facilitate data interpretation in future trials. Based on the 
available clinical data for therapeutic strategies in glioblastoma, some conclusions, 
illustrated in Figure 1, can be drawn: 
- The RANO criteria represent the currently most accepted approach for diagnosis of 
progression and response in recurrent glioblastoma and the international consensus 
MRI protocol provides a good working tool for practice and trials. 
- The evidence for repeat surgery or reirradiation is limited, calling for prospective 
randomized trials determining their efficacy. 
- Nitrosoureas still represent the most widely accepted standard option for systemic 
chemotherapy at recurrence  
- MGMT promotor methylation may emerge as a predictive biomarker for benefit of 
TMZ rechallenge in recurrent glioblastoma, indirectly disencouraging treatment with 
TMZ for MGMT promoter-unmethylated tumors. The best schedule of TMZ at 
recurrence has not been defined, and may be scheduling matters less than 
previously thought. 
- There is clinical activity of bevacizumab monotherapy at recurrence, but an effect 
on overall survival is uncertain. Prospective data from phase II trials pointed towards 
efficacy of a combination regimen with nitrosoureas which was not confirmed in 
phase III. 
- Immunotherapeutic concepts are currently under evaluation for newly diagnosed 
and recurrent glioblastoma, with promising preliminary data for rindopepimut, 
warranting further efforts exploring further immunotherapeutic agents even in the 
recurrent setting, e.g., immune checkpoint inhibitors 
 
In summary, treatment concepts for patients with recurrent glioblastoma in clinical 
practice should be somewhat individualized and take into account age, performance 
status, MGMT promoter methylation status and response to previous regimens as 
well as quality of life with regard to expected toxicities. To improve evidence on 
treatment options, patients should be treated within carefully designed clinical trials. 
Rebiopsies may be required more often to ascertain molecular tumor status as more 
targeted therapies become available. Further preclinical and clinical investigation is 
needed to improve the prognosis for patients with recurrent glioblastoma. 
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6. Tables 
  
Table 1. Nitrosourea monotherapy and combination regimens1 
Design No. of relapse, 
no. of patients 
Pre-treatment Treatment ORR (%) PFS-6 (%) mPFS 
(months) 
mOS 
(months) 
Ref. 
Single-arm monotherapy trials 
Phase  II n=40 RT BCNU 80 mg/m2 on days 1-3 q8wk 
for max 6 cycles 
15% 17.5% NA 7.5 [47] 
Phase II 1st, n=27 RT/TMZ+TMZ FOT IV 100 mg/m2 qwk for 3 wks 
(induction), then q3wk (maintenance) 
30% 48.2% 5.7 9.1 [48] 
Phase II 1st, n=43 RT/TMZ+TMZ FOT 75-100 mg/m2 qwk for 3 wks, 
after 5-wk break 100 mg/m2 q3wk for 
≤1 yr 
7% 20.9% 1.7 6.0 [49] 
Phase II 1st, n=50 RT/TMZ+TMZ FOT 100 mg/m2 qwk for 3 wks 
(induction), 4- to 6-wk break, then 
FOT 100 mg/m2  q3wk (maintenance) 
18% 52% 6.1 8.1 [51] 
Phase II 1st, n=40 RT/TMZ+TMZ FOT IV 80 mg/m2 on days 1, 15, 30, 
45, and 60 (induction), then 80 mg/m2 
q4wk (maintenance) 
25% 61% 6.1 11.1 [50] 
Randomized trials 
Phase II, 
randomized 
 
1st, CTR: n=29 
(BCNU), n=27 
(TMZ), n=52 
evaluable; 
n=54 (ERL) 
RT+/-Chemo 
(64% CTR/ 65% 
ERL) 
CTR (BCNU 60 mg/m2 on days 1-3 
q8wk (max 5 cycles) 
or TMZ 150-200 mg/m2 (5/28)  
or 
ERL 150-200 mg/d 
10% (CTR),  
4% (ERL) 
24% (CTR),  
11% (ERL)  
 
2.4 (CTR),  
1.8 (ERL) 
7.3 (CTR),  
7.7 (ERL) 
[57] 
Phase III, 
randomized 2:1 
1st: n=70 
(CCNU), n=129 
(Enzastaurin) 
2nd: n=21 
(CCNU), n=45  
(Enzastaurin) 
RT+/-Chemo (NA, 
no nitrosourea) 
CCNU 100-130 mg/m2 q6wk 
or 
Enza 500 mg/d (1125 mg on day 1) 
4% (CCNU), 
3% (Enza) 
19% (CCNU),  
11% (Enza) 
1.6 (CCNU),  
1.5 (Enza) 
7.1 (CCNU), 6.6 
(Enza) 
[53] 
Phase III, double-
blind, randomized 
1:2:2 
 
1st,n=65 (CCNU) 
n=131 (CED), 
n=129 
(CED+CCNU) 
RT/TMZ+TMZ CCNU 110 mg/m2 q6wk + placebo  
or 
CED 30 mg/d 
or 
CED 20 mg/d + CCNU 110 mg/m2 
q6wk 
8% (CCNU), 
14 %(CED), 
16%, (CED+ 
CCNU) 
24.5% (CCNU),  
16% (CED),  
34.5 %  
(CED+CCNU) 
2.7 (CCNU), 
3.1 (CED), 
4.2 (CED+CCNU) 
9.8 (CCNU), 
8.0 (CED), 
9.4 (CED+CCNU) 
[52] 
Phase II, 
randomized 
1st, n=50 (BEV),  
n=46 (CCNU),  
n=44 
(BEV+CCNU) 
RT/TMZ+TMZ BEV 10 mg/kg q2wk 
or 
CCNU 110 mg/m2 q6wk 
or 
BEV q2wk +CCNU 90 (-110) mg/m2 
q6wk 
38% (BEV),  
5% (CCNU),  
34% 
(BEV+CCNU) 
18% (BEV),  
11% (CCNU),  
41% 
(BEV+CCNU) 
3 (BEV),  
2 (CCNU),  
11 (BEV+CCNU) 
8 (BEV),  
8 (CCNU),  
11 (BEV+CCNU) 
[54] 
Phase II, 
randomized 2:1:1, 
placebo-controlled 
NA, n=79 
(CCNU+G), 
n=39 (G), 
n=40 (CCNU+P) 
NA CCNU q6w +Galunisertib (CCNU+G) 
or  
Galunisertib (300mg/d) for 14 days 
q28d alone (G) 
1% 
(CCNU+G), 
5% (G), 
0% (CCNU+P) 
NA 1.8 (CCNU+G), 
1.8 (G), 
1.9 (CCNU+P) 
6.7 (CCNU+G), 
8 (G), 
7.5 (CCNU+P) 
[55] 
or 
CCNU q6wk +placebo (P+CCNU) 
Phase II, 
randomized 
1st,2nd, 3rd, 
n=68 evaluable 
pts 
RT/TMZ+TMZ+/- 
other 
BEV 10 mg/kg q2wk 
or 
BEV 5 mg/kg q3wk+ 
CCNU 90 mg/m2 q6wk 
NA NA 4.1 (BEV),  4.3 (BEV+CCNU) 
NA (ITT); 
Pts with 1st 
relapse: 
8.8 (BEV),  
13.1 
(BEV+CCNU) 
[58] 
Phase III, 
randomized 2:1 
1st, 
n=288 
(CCNU+BEV), 
n=149 (CCNU) 
RT/TMZ+TMZ 
CCNU 90 mg/m2 q6wk + BEV 10 
mg/kg q2wk 
or 
CCNU 110 mg/m2 q6wk 
NA NA 
4.2 
(CCNU+BEV), 
1.5 (CCNU) 
9.1 
(CCNU+BEV), 
8.6 (CCNU) 
[56] 
Single-arm combination therapy trials 
Phase II 2nd, n=42 RT+ TMZ BCNU (100 mg/m2) on days 1+CPT-
11 (175 mg/m2) on days 1-3 q1wk for 
4 wks, cycles of 6 wks 
21.4% 30.3% 3.9 11.7 [60] 
Phase II NA, n=38 RT+/-chemo 
(10.5%) 
BCNU (150 mg/m2) +TMZ 550 mg/m2  
q6wks 
5.6% 21% 2.5 7.8 [61] 
Prospective NA, n=20 (n=10 
evaluable for 
outcome) 
RT/TMZ+TMZ TMZ 150 mg/m2  for 7 days q14d  
+FOT 110 mg/m2 monthly q14d 
NA 40% 4.3 NA [62] 
Phase II 1st,n =54 RT/TMZ+TMZ BEV 10 mg/kg q2wk 
+FOT 75 mg/m2 on day 1 and day 8, 
then q3wk 
 
52% 42.6% 5.2 9.1 [59] 
Abbreviations: BCNU, carmustine; CCNU, lomustine; CED, cediranib; CPT-11, irinotecan; CTR, control arm; d, day; Enza, enzastaurin; ERL, erlotinib; FOT, fotemustine; G: Galunisertib; ITT, 
intention-to-treat population; max, maximum; mOS, median overall survival; mPFS, median progression-free survival; NA, not available; P, placebo; PFS, progression-free survival; pts, patients; q, 
every; Ref, reference; RT, radiotherapy; TMZ, temozolomide; wk, week; 
1 All data presented for glioblastoma patients only. In case, the study was designed for different patient populations, only the respective data for glioblastoma patients were included in the table.
Table 2. Temozolomide monotherapy and combination regimens1/2 
Design No. of relapse, no. 
of patients 
Pre-treatment Treatment ORR (%) PFS-6 mPFS 
(months) 
mOS  
(months) 
Ref. 
Single-arm monotherapy trials 
Phase II 1st, n=126  RT +/- nitrosourea 
(40%) 
Chemo-naïve pts: TMZ 200 mg/m2/d for 5 
days q28d 
Pts with previous chemotherapy: TMZ 150 
mg/m2/d for 5 days q28d 
8% 18% 2.1 5.4 [45] 
Phase II 2nd, n=22 RT+PCV TMZ 150 mg/m2/d for 5 days q28d 23% 32% NA 7.6 [65] 
Phase II 2nd, n=42 RT+PCV TMZ 150 mg/m2/d for 5 days q28d 19% 24% NA 7.0 [66] 
Phase II NA, n=28 RT (all but 1) +/- 
chemo (mostly 
nitrosourea) 
TMZ 75 mg/m2/d for 42 days q70d 0% 19% 2.3 7.7 [123] 
Phase II 1st, n=12;  
2nd and 3rd , n=9 
RT (all) +/- 
nitrosourea (43%) 
TMZ 150 mg/m2  for 7 days q14d  10% 48% 4.9 NA [124] 
Prospective 1st, n=13 RT TMZ 200 mg/m2/d for 5 days q28d, max 4 
cycles 
 
NA 21% NA NA [67] 
Phase II 1st, n=33 RT TMZ 75 mg/m2/d for 21 days q28d 9% 30% 3.7 9.2 [125] 
Prospective NA, n=12 RT+TMZ+/-ACNU 
(n=1), PCV (n=2) 
TMZ 40 mg/m2/d 17% NA 6 11 [126] 
Prospective NA, n=19 RT (all) +/- chemo 
(mostly nitrosourea) 
TMZ 150-200 mg/m2/d for 5 days q28d 24% 22% 2.2 9.9 [64] 
Phase II NA, n=64 RT+/-chemo (n=41 
nitrosourea, n=9 
TMZ+nitrosourea) 
TMZ 150 mg/m2  for 7 days q14d NA 43.8% 5.5 NA [127] 
Phase II 1st,  n=48; 
≥2: n=20 
RT+/- chemo 
(previous non-
nitrosourea: chemo 
n=7; nitrosourea: 
n=33) 
TMZ 200 mg/m2 initial dose, then 9 
consecutive doses at 90-100 mg/m2 q12h for 
28 days; 
31% 35% 4.2 8.8 [128] 
Phase II NA, n=27 GB, n=20 
AG 
RT+chemo (93% 
TMZ 1st line, 49% at 
2nd recurrence), 
some nitrosourea 
TMZ 85 mg/m2 for 21 days q28d 7% 0 
 
 
NA 5.11 [129] 
Phase II 1st,  
n=33 (early), 
n=27 (extended) 
n=28 (rechallenge) 
per timing of 
progression 
during/after adjuvant 
therapy 
RT+TMZ/TMZ 50 mg/m2/d continuous (max. 1 year) NA 23.9% (all 
groups),  
27.3% (early), 
7.4% 
(extended),   
35.7% 
(rechallenge) 
NA (all groups) 
3.6 (early), 
1.8 (extended) 
3.7 
(rechallenge) 
9.3  
(all groups) 
[68] 
Phase II 1st, n=38 RT+TMZ/TMZ 40-50 mg/m2/d 5% 32.5% 3.9 9.4 [130] 
Phase II 1st, n=27 RT+TMZ/TMZ TMZ 130 mg/m2  for 7 days q14d, max. 1 year 11.1% 33.3% 4.2 6.9 [131] 
Phase II 1st, n=58 RT+TMZ/TMZ 75-100 mg/m2/d for 21 days q28d 13% 11% 1.8 11.7 [132] 
Phase II 1st, n=12, 2nd, n=18, 
≥3, n=10 
RT+TMZ/TMZ+ 
other 
TMZ 150 mg/m2  for 7 days q14d NA 10% 1.8 5 [133] 
Randomized trials 
Phase II, 
randomized 
1st,   
n=112 (TMZ), n=113 
(PCB) 
RT +/- nitrosourea 
(65% TMZ group,  
68% PCB group 
 
TMZ 150-200 mg/m2/d for 5 days q28d  
or 
PCB 125-150 mg/m2/d for 28 days  q56d 
5% (TMZ),  
5% (PCB) 
 
 
21% (TMZ), 
8% (PCB) 
 
 
 
2.8 (TMZ), 
1.9 (PCB) 
 
NA [46] 
Phase II, 
randomized  
1st GBM and AA; 
n=87 (TMZ 5/28),  
n=81 (TMZ 21/28), 
n=162 (PCV) 
 
RT TMZ 200 mg/m2 for 5 days q28d (TMZ 5/28) 
or 
TMZ 100 mg/m2 for 21 days q28d (TMZ 
21/28) 
or 
PCV 
NA NA 5.02 (TMZ 
5/28), 
4.22 (TMZ 
21/28), 
3.62 (PCV) 
8.52 (TMZ 
5/28), 
6.62 
(TMZ 21/28), 
6.72 (PCV) 
[69] 
Phase II NA, n=10 
(TMZ+BEV), n=13 
ETO+BEV) 
RT+TMZ/TMZ 
+BEV+/-other 
TMZ 50 mg/m2/d  
+ BEV 10 mg/kg q2wk 
or 
ETO 50 mg/m2/d for 21 days q28d 
+ BEV 10 mg/kg q2wk 
0% 4.4% 1.0 
(TMZ+BEV), 
1.9 ETO+BEV) 
NA [74] 
Phase II, 
randomized 
1st, n=39 (TMZ),  
n=41 (A), 
n=39 (A+TMZ) 
RT+TMZ/TMZ TMZ 75 mg/m2/d for 21 days q28d 
(TMZ) 
or 
Afatinib 40mg/d (A) 
or 
Afatinib 40mg/d+ TMZ 75 mg/m2/d for 21 
days q28d 
(A+TMZ) 
19% (TMZ) 
2.4% (A),  
5% (A+TMZ) 
23% (TMZ) 
3% (A) 
10% (A+TMZ) 
1.9 (TMZ) 
1 (A) 
1.5 (A+TMZ) 
10.6 (TMZ) 
9.8 (A) 
8 (A+TMZ) 
[70] 
Phase II, 
randomized 
1st, n=105 RT+TMZ/TMZ TMZ 120 mg/m2  for 7 days q14d (Arm A) 
or TMZ 80 mg/m2/d for 21 days q28d (Arm B) 
8% (Arm A) 
16% (Arm B) 
17.1% (Arm A) 
25% (Arm B) 
NA 9.8 (Arm A) 
10.6 (Arm B) 
[71] 
Single-arm combination therapy trials 
The combination of TMZ+nitrosoureas is reported in Table1 
Phase II 1st, n=15 
2nd, n=15 
3rd, n=2 
RT/TMZ+TMZ+/- 
other (BEV in n=4) 
TMZ 50 mg/m2/d + 
BEV 10 mg/kg q2wk 
28% 18.8% 3.6 8.5 [72] 
Phase I/II NA, n=15 NA TMZ 50 mg/m2/d q3wk  
+ BEV 10 mg/kg q3wk 
NA 6.7%  2.4 3.6 [73] 
Phase II 1st, n=32 RT+TMZ/TMZ TMZ 150 mg/m2  for 7 days q14d+ 
BEV 10 mg/kg q2wk 
40.6% 21.9% 4.2 7.3 [75] 
Phase II NA, n=34 
(TMZ+IFN), n=29 
(TMZ+pIFN) 
RT+/-chemo (no 
TMZ or IFN) 
TMZ 150-200 mg/m2/d for 5 days q28d + IFN-
α2b: 4 MU/ m2 3x/wk  (TMZ+IFN) 
and 
TMZ 150-200 mg/m2/d for 5 days q28d + 
Long-acting PEG-IFN-α2b 0.5 µg/kg/wk 
(TMZ+pIFN) 
12% 
(TMZ+IFN) 
 
3% 
(TMZ+pIFN) 
31% 
(TMZ+IFN) 
 
38% 
(TMZ+pIFN) 
3.6 (TMZ+IFN) 
 
4.4 
(TMZ+pIFN) 
7.2 (TMZ+IFN) 
 
10  
(TMZ+ pIFN) 
[76] 
Phase II NA, 1-5 treatment 
lines, n=32 
RT+/- chemo (TMZ, 
BEV and others) 
TMZ 50 mg/m²/d  + 
Sorafenib 400 mg 2×/d 
3% 9.4% 1.5 9.6 [77] 
Phase II NA, n=34 NA/TMZ (all) TMZ 472 mg/m2 q28d 
+O(6)-BG 1-h infusion of 120 mg/m2, followed 
immediately by a 48-h infusion of 30 mg/m2 
q28d 
3% 9 1.7 4.5 [78] 
Phase I NA, n=91 RT/chemo TMZ 200 mg/m2/d for 5 days q28d + 
CPT-11 40 mg/m2 to 375 mg/m2 IV on weeks 
1, 2, 4, and 5 of each 6-wk cycle 
12% 27.3% 2.6 NA [79] 
Phase II 1st, n=22 RT+/- chemo (9%, 
no TMZ) 
TMZ 200 mg/m2 for 5 days q28d + 
Liposomal DOX 40 mg/m2 IV on day 1 q4wk 
18% 32% 3.6 8.2 [82] 
Phase II NA, n=20 RT+nitrosourea+ 
CIS 
TMZ 200 mg/m2 on days 2-6 q4wk  
+CIS 40 mg/m2, on days 1 and 2 q4wk 
10% 35% 4.9 NA [80] 
Phase II 1st, n=50 RT TMZ 130 mg/m2 bolus followed by 9 doses of 
70 mg/m2 q12h (total of 5 days) from day 2 
q4wk, from 2nd cycle: 100 mg/m2 mg/m2 q12h 
for 5 days q4wk 
+CIS 75 mg/m2 on day 1 q4wk 
20.4% 34% 4.2 11.2 [81] 
Phase I NA, n=18 NA ABT-414 0.5-1.5 mg/kg q14d + TMZ 150-200 
mg/m2 for 5 days q28d 
22.2% NA NA NA [83] 
Abbreviations: (6)-BG: O6-benzylguanine; A, afatinib; AA, anaplastic astrocytoma; AG, anaplastic glioma; BEV, bevacizumab, CIS, cisplatin; d, day; DOX, doxorubicine; ETO, etoposide; GB, glioblastoma; IFN, 
interferon; mOS, median overall survival; mPFS, median progression-free survival; NA, not available; PCB, procarbacine; PCV, procarbazine, CCNU, and vincristine; PCB: procarbazine, PFS, progression-free 
survival; pts, patients; q, every; Ref, reference; RT, radiotherapy; TMZ, temozolomide. wk, week; 
1 Data presented for glioblastoma patients only. In case, the study was designed for different patient populations, only the respective data for glioblastoma patients were included in the table  
2 Reporting of data for glioblastoma patients only was not possible due to lack of reporting data seperately in the studies of Berrocal and colleagues [129] with 27 patients with glioblastoma, 15 with anaplastic 
astrocytoma and 5 with miscellaneous brain tumors and the study of Brada and colleagues [69] with 277 patients with glioblastoma, 53 with anaplastic astrocytoma and 20 with miscellaneous brain tumors.  
  
Table 3. Bevacizumab monotherapy and combination regimens1/2 
Design 
 
No. of relapse, 
no. of patients Pre-treatment Regimen ORR (%) PFS-6
 (%) mPFS (months) mOS (months) Ref.  
Single-arm monotherapy trials 
Phase II 1st, n=48 RT/TMZ+  TMZ BEV 10 mg/kg q2wk, addition of CPT-11 at progression 35% 
29% 
 3.7 7.2 [86] 
Phase II 1
st and other, 
n=50 
RT/TMZ+ TMZ+ 
other BEV 15 mg/kg q3wk 
NA 
 25% 2.8 6.5 [87]  
Phase II 1st, n=29 RT/TMZ+ TMZ BEV 10 mg/kg q2wk 27.6% 33.9% 3.3 10.5 [88] 
Randomized trials 
Phase II, 
randomized 
1st, 
n=50 (BEV),  
n=46 (CCNU),  
n=44 
(BEV+CCNU) 
RT/TMZ+ TMZ 
BEV 10 mg/kg q2wk 
or 
CCNU 110 mg/m2 q6wk 
or 
BEV q2wk +CCNU 90 (-110) mg/m2 q6wk 
38 (BEV),  
5 (CCNU),  
34 (BEV+CCNU) 
18 (BEV),  
11 (CCNU),  
41 (BEV+CCNU) 
3 (BEV),  
2 (CCNU),  
11 (BEV+CCNU) 
8 (BEV),  
8 (CCNU),  
11 (BEV+CCNU) 
[54] 
Phase II, 
randomized 
1st,2nd, 3rd, 
n=68 evaluable 
pts 
RT/TMZ+ TMZ+/- 
other 
BEV 10 mg/kg q2wk 
or 
BEV 5 mg/kg q3wk+ 
CCNU 110 mg/m2 q6wk 
NA NA 4.1 (BEV),  4.3 (BEV+CCNU) 
NA (ITT); 
Pts with 1st 
relapse: 
8.8 (BEV),  
13.1 
(BEV+CCNU) 
[58] 
Phase III, 
randomized 
2:1 
1st, 
n=288 
(CCNU+BEV), 
n=149 (CCNU) 
RT/TMZ+TMZ 
CCNU 90 mg/m2 q6wk + BEV 10 mg/kg q2wk 
or 
CCNU 110 mg/m2 q6wk 
NA NA 
4.2 
(CCNU+BEV), 
1.5 (CCNU) 
9.1 
(CCNU+BEV), 
8.6 (CCNU) 
[56] 
Phase II, 
randomized 
1st, n=69 (BEV) 
2nd, n=16 (BEV) 
1st, n=66 
(BEV+CPT) 
2nd, n=16 
(BEV+CPT) 
RT/TMZ+ TMZ 
BEV 10 mg/kg q2wk 
w/o  
CPT-11 340 mg/m2 or 125 mg/m2 q2wk 
28 (BEV),  
38  
(BEV+CPT-11) 
42.6 (BEV) 
50.3 (BEV+CPT-
11) 
 
 
4.2 (BEV) 
5.6  
(BEV+CPT-11) 
 
9.2 (BEV) 
8.7  
(BEV+CPT-11) 
 
[85] 
Phase II, 
randomized 
1st, n=55 (BEV), 
 n=55 
(BEV+Carbo) 
RT/TMZ+ TMZ 
BEV 10 mg/kg q2wk 
w/o  
Carbo (AUC 5) q4wk 
6% (BEV), 
14% 
(BEV+Carbo) 
18% (BEV), 
15% 
(BEV+Carbo) 
3.5 (BEV), 
 3.5 (BEV+Carbo) 
7.5 (BEV), 
6.9 (BEV+Carbo) [84] 
Phase II, 
randomized 
1st, n=41 (BEV), 
 n=49 
(BEV+VOR) 
RT/TMZ+ TMZ 
BEV 10 mg/kg q2wk  
w/o  
VOR 400mg/d for 7 days q2wk 
NA NA 3.6 (BEV), 4.2 (BEV+VOR) 
7.0 (BEV), 
8.3 (BEV+VOR) [89] 
Phase II, 
randomized 
1:2 
NA, n=38 
(BEV+P), 
 n=83 
(BEV+Dasa) 
NA 
BEV 10 mg/kg q2wk+P 
w/o  
Dasa 100 mg twice/d  
26.5% (BEV+P), 
18.3% 
(BEV+Dasa) 
18.4% (BEV+P), 
27.2% 
(BEV+Dasa) 
NA 7.9  (BEV+P), 7.2 (BEV+Dasa) [90] 
Single-arm combination therapy trials 
The combination of BEV+nitrosoureas is reported in Table 1 
The combination of BEV+TMZ is reported in Table 2 
NA NA, n=11 GB, n=10 other glioma 
NA 
 
BEV 5 mg/kg every other wk for 2 doses  
+ CPT-11 125 mg/m2 qwk for 4 doses, followed by 
2-wk rest period 
43% NA NA NA [91] 
Design 
 
No. of relapse, 
no. of patients Pre-treatment Regimen ORR (%) PFS-6
 (%) mPFS (months) mOS (months) Ref.  
Phase II NA, n=23 RT and/or chemo BEV 10 mg/kg q2wk+ CPT-11 340 mg/m
2 (with 
EIAED) or 125 mg/m2 (without EIAED) q2wk 61% 30% 4.6 9.2 [93] 
Phase II NA, n=35 RT/TMZ+ TMZ+ other 
Cohort 1: 
BEV 10 mg/kg q2wk + CPT-11 340 mg/m2 (with 
EIAED), or 125 mg/m2 (without EIAED), q2wk (6-wk 
cycle) 
Cohort 2: 
BEV 15 mg/kg IV q21d + CPT-11 340 mg/m2 (with 
EIAED) or 125 mg/m2 (without EIAED) on days 1, 8, 
22, and 29 (6-wk cycle) 
NA 46%3  5.53 9.73 [92] 
Phase II  NA, n=57 RT/TMZ+TMZ BEV 10 mg/kg  +CPT-11 200 mg/m2 q2wk NA 37% NA NA [94] 
Phase II NA, n=32 NA BEV 10 mg/kg q2wk  + CPT-11 340 mg/m
2 IV (with 
EIAED) 125 mg/m2  (without EIAED) q2wk 25% 28% 5.2 7.9 [95] 
Phase II 
1st within last 6 
months of first-line 
treatment, n=43 
(n=32 evaluable) 
RT/TMZ+ TMZ 
BEV 5-10 mg/kg q2wk  
+ CPT-11 340 mg/m2 IV (with EIAED) 125 mg/m2  
(without EIAED) q2wk 
+ CET 400 mg/m2 IV as loading dose, followed by 
250 mg/m2/wk 
34% 30% 3.7 6.7 [96] 
Phase II 
1st, n=27, 
2nd, n=11, 
3rd, n=2 
RT/TMZ+ TMZ+ 
other (no BEV) 
BEV 10 mg/kg q2wk  
+ CPT-11 340 mg/m2 IV (with EIAED) 125 mg/m2  
(without EIAED) q2wk 
+ Carbo (AUC 5) q4wk 
33% 46.5% 5.9 8.3 [97] 
Phase II 
1st, n=14, 
2nd, n=8 
3rd, n=5 
RT+chemo 
BEV 10 mg/kg  q2w  
+ ETO 50 mg/m2 daily for 21 consecutive days each 
month 
22% 44.4% 4.1 10.2 [98] 
Phase II 
1st: 52%; 
2nd: 36%; 
3rd: 12% 
RT/TMZ+ TMZ 
BEV  10 mg/kg  q2wk  
+ ERL 500 mg/kg/d (with EIAED) or, 200 mg/kg/d 
(without EIAED)  
50% 29.2% 4.1 10.3 [100] 
Phase II NA, n=13 RT/TMZ+ TMZ+BEV 
BEV 10 mg/kg q2wk starting on day 8 + 
temsirolimus 25 mg qwk starting on day 1 0% NA 1.8 3.5 [99] 
Phase II NA, n=54 RT/TMZ+ TMZ+/-other 
BEV  5 mg/kg  q2wk  
+ Sorafenib 100-200 mg/d 18.5% 20.4% 2.9 5.6 [101] 
Phase II ≤2 relapses, n=24 (interim analysis) 
NA (No anti-
VEGF, no HDAC-
I) 
BEV 10 mg/kg q2wk 
+Panobinostat 30mg 3 times/wk 29.2% 30.4% 5 9 [102] 
Phase II NA, n=40 NA BEV 10 mg/kg q2wk +VOR 400mg/d for 7 days q2wk 22.5% 30% NA 10.4 [103] 
Abbreviations: AUC, area under the curve; BEV, bevacizumab; CET, cetuximab; Carbo, carboplatin; CPT-11, irinotecan; d, day; Dasa: Dasatinib; EIAED, enzyme-inducing antiepileptic drugs; ERL, erlotinib; ETO, 
etoposide; GB, glioblastoma; HDAC-I: histone deacetylase-inhibitors, ITT: intention-to-treat-population; mOS, median overall survival; mPFS, median progression-free survival; NA, not available; P: placebo; PFS, 
progression-free survival; pts, patients; q, every; Ref, reference; RT, radiotherapy; TMZ, temozolomide,; VEGF: vascular endothelial growth factor, VOR: vorinostat; w/o, with or without; wk, week; 
1 Data presented for glioblastoma patients only. In case, the study was designed for different patient populations, only the respective data for glioblastoma patients were included in the table  
2 Reporting of data for glioblastoma patients only was not possible due to lack of reporting data for separately for one study [91] where combined data of patients were presented (11 patients with glioblastoma and 10 
patients with anaplastic glioma)  
3 Data presented for both cohorts combined 
 
  
Table 4: Targeted agents, monotherapy and combination regimens1/2 
Design No. of relapse, no. of patients 
Pre-
treatment Regimen Target ORR PFS-6 
mPFS 
(months) 
mOS 
(months) Ref.  
Phase II NA, n=20 RT+chemo Gefitinib 250 qd and everolimus 70 mg qw 
EGFR (Gefitinib), mTOR 
(Everolimus) 14% NA 2.6 5.8 [108] 
Phase II NA, n=31 
RT or 
RT/TMZ+ 
TMZ 
Cediranib 45 mg/d VEGFR1-3, c-Kit, PDGFR 27% 25.8 3.8 7.5 [106] 
Phase II 
 
NA/34% 2nd,  
total: n=78 (125mg), 
n=46 (175mg) 
NA/Previous 
AAT (n=42) 
XL184  
125 mg or 
175 mg qd 
c-MET, VEGFR2, 
RET NA 
NA (125 mg) 
21% (175 mg) NA NA 
[134, 
135]  
Phase II NA, n=35 NA Pazopanib 800 mg qd VEGFR1-3, c-Kit, PDGFR 6% 3% 2.8 NA [136] 
Phase II 1st, n=37 RT+chemo Sagopilone16 mg/m2 q21d Microtubule 0% 6.7% 1.4 7.6 [137] 
Phase II 
 
1st, n=39 
2nd, n=3 (excluded from 
efficacy analysis) 
RT/TMZ+ 
TMZ Aflibercept  4 mg/kg q2wk  VEGF, PlGF 18% 7.7 2.8 9.0 [138]  
Phase II NA, n=66 NA VOR 400mg/d  for 14 days of a 21-day cycle Histone deacetylase 3% 15.2% 1.9 5.7 [113] 
Phase II ≤3 relapse, n=16 
RT/TMZ+ 
TMZ+/-other 
(BEV 48%) 
AMG-102: 10 or 20mg/kg q2k HGF 2% NA 1.0 (10 mg) 1.2 (20 mg) 
6.5 (10 mg) 
5.4 (20 mg) [139] 
Phase II 1
st (n=18), 2nd (n=7), 3rd 
or more (n=7) 
RT+chemo+/
-others Vandetanib  300 mg qd 
VEGFR2, EGFR, 
“rearranged-during-
transfection oncogene” 
13% 6.5% 1.3 6.3 [140] 
Phase II ≤2 relapse, n=16 RT/TMZ+ TMZ+/-other 
Sunitinib 50mg/d for 4 wk every 
6 wks 
VEGFR1-2, c-Kit, PDGFR, 
FLT3,CSF-1R,  RET 0% 16.7% 1.4 12.6 [141] 
Phase II NA, n=37 NA 
VOR 400mg/d  for 14 days of a 
21-day cycle 
Bortezomib 1.3 mg/m2 on days 
1, 4, 8, and 11 
Histone deacetylase 
(VOR),  
Proteasom (Bortezomib) 
3% 0% 1.5 3.2 [114] 
Phase II NA, n=56 RT+chemo Erlotinib 150 mg/d, sorafenib 400mg twice/d 
EGFR (Erlotinib), VEGFR, 
PDGFR, Raf kinases 5% 14% 2.5 5.7 [115] 
Phase I NA, n=18 NA 
ABT-414 0.5-1.5 mg/kg q14d + 
TMZ 150-200 mg/m2 for 5 days 
q28d 
EGFR (ABT-414) 22.2% NA NA NA [83] 
Phase II 1
st , n=13 
2nd, n=12 
RT/TMZ+ 
TMZ (n=13), 
BEV at 1st 
relapse 
(n=12) 
Nintedanib 200 mg bid VEGFR1-3, FGFR1-3, PDGFR 0% NA 1 6 [142] 
Phase II NA, n=41 RT+ chemo, others 
Pazopanib 400 mg qd, 
Lapatinib 1000 mg ad 
VEGFR1-3, c-Kit, PDGFR 
(Pazopanib), EGFR 
(Lapatinib) 
5%  7.5% 1.9 NA [143] 
Phase II NA, n=32 BEV naïve, n=31 BEV resistant 
RT/TMZ+ 
TMZ +/- BEV 
or other 
Sunitinib 37.5 mg qd 
VEGFR1-2, c-Kit, PDGFR, 
FLT3, 
CSF-1R,  RET 
10% (BEV-
naïve) 
0% (BEV-
resistant) 
10.4% (BEV-
naïve) 
0% (BEV-
resistant) 
1 (BEV-naïve) 
1 (BEV-
resistant) 
9.4 (BEV-
naïve), 4.4 
(BEV-resistant) 
[144] 
Phase II 
≤2 relapse, n=31 (BEV-
naïve), n=25 (previous 
BEV) 
RT/TMZ+ 
TMZ+/-other 
Verubulin 3.3 mg//m2  qwk for 3 
wks, every 4 wks 
Microtubule destabilizing, 
vascular disruption 
10%(BEV-
naïve), 4.2% 
(previous BEV) 
14%(BEV-
naïve), 8% 
(previous BEV) 
1.6 (BEV-
naïve), 0.8 
(previous BEV) 
9.4 (BEV-
naïve), 3.4 
(previous BEV) 
[145] 
Phase II 
1st, n=50, 
overexpression of at 
least 2 putative 
dasatinib targets 
RT/TMZ+ 
TMZ Dasatinib 100 mg -200 twice/d,  
SRC, c-KIT, EPHA2, 
PDGFR 0% 6% 1.7 7.9 [111] 
Phase II NA, n=7 (Arm A), n=15 (Arm B, 12 evaluable) 
RT/TMZ+ 
TMZ 
3 doses of Selinexor 50 mg/m2 
prior to surgery, Selinexor 50 
mg/m2 after surgery (Arm A) 
and 
Selinexor 50 mg/m2 q2wk (Arm 
B) 
Nuclear retention via 
XPO1 of p53, pRB, 
CDKN2A, p21 and FOXO 
17% NA NA NA [109] 
Phase II 1st, n=33 RT/TMZ+ TMZ PX-866 8mg/d PI3K 3% 17% NA NA [110] 
 
Randomized trials 
Phase II, 
randomized 
 
1st , 
n=41 (500mg) 
n=40 (200mg) 
RT, TMZ and 
others 
 
CIL 500  
or 2000 mg, 
2×/wk  
αvβ3/αvβ5 integrins 5% (500 mg) 13% (2000 mg) 
10% (500 mg)2 
15%  
(2000 mg)2 
NA 6.5
2 (500 mg) 
9.92 (2000 mg) [112]  
Phase II, 
randomized 
 
1st, CTR: n=29 (BCNU), 
n=27 (TMZ), n=52 
evaluable; 
n=54 (ERL) 
RT+/-Chemo 
(64% CTR/ 
65% ERL) 
CTR (BCNU 60 mg/m2 on days 
1-3 q8wk (max 5 cycles)or TMZ 
150-200 mg/m2 (5/28)  
or 
ERL 150-200 mg/d 
EGFR (ERL) 10% (CTR),  4% (ERL) 
24% (CTR), 
11% (ERL)  
 
2.4 (CTR), 1.8 
(ERL) 
7.3 (CTR), 7.7 
(ERL) [57] 
Phase II, 
randomized 1
st and 2nd , total n=26 RT+ chemo 
CIL 500  
or 2000 mg × 3 doses, 
resection, then 2000 mg 2×/wk  
αvβ3/αvβ5 integrins NA 12% (both arms) 1.9 (both arms) NA [146]  
Phase III, 
double-blind, 
randomized 
1:2:2 
 
1st, 
 n=65 (CCNU) 
 n=131 (CED), 
n=129 (CED+CCNU) 
RT/TMZ+ 
TMZ 
CCNU 110 mg/m2 q6wk + 
placebo  
or 
CED 30 mg/d 
or 
CED 20 mg/d + CCNU 110 
mg/m2 q6wk 
VEGFR1-3 and PDGFR 
(CED) 
8% (CCNU), 
14 %(CED), 
16%, (CED+ 
CCNU) 
24.5% 
(CCNU),  
16% (CED),  
34.5 % 
(CED+ CCNU) 
2.7 (C2CNU), 
3.1 (CED11), 
4.2 (CED+ 
CCNU) 
9.8 (CCNU), 
8.0 (CED), 
9.4 (CED+ 
CCNU) 
[52] 
Phase III, 
randomized 
2:1 
1st: n=70 (CCNU), 
n=129 (Enzastaurin) 
2nd: n=21 (CCNU), 
n=45  
(Enzastaurin) 
RT+/-Chemo 
(NA, no 
nitrosourea) 
CCNU 100-130 mg/m2 q6wk 
or 
Enza 500 mg/d (1125 mg on 
day 1) 
Protein kinase C, PI3K, 
AKT 
4% (CCNU), 
3% (Enza) 
19% (CCNU), 
11% (Enza) 
1.6 (CCNU), 
1.5 (Enza) 
7.1 (CCNU), 
6.6 (Enza) [53] 
Phase II, 
randomized 
2:1:1, placebo-
controlled 
NA, n=79 (CCNU+G), 
n=39 (G), 
n=40 (CCNU+P) 
NA 
CCNU q6w + Galunisertib 
(CCNU+G) 
or  
Galunisertib (300mg/d) for 14 
days q28d alone (G) 
or 
CCNU q6w +P (P+CCNU) 
 TGFβR1 (G) 
 
1% 
(CCNU+G), 
5% (G), 
0% (CCNU+P) 
NA 
1.8 (CCNU+G), 
1.8 (G), 
1.9 (CCNU+P) 
6.7 (CCNU+G), 
8 (G), 
7.5 (CCNU+P) 
[55] 
Phase II, 
randomized 
1st, n=39 (TMZ),  
n=41 (A), 
n=39 (A+TMZ) 
RT/TMZ+ 
TMZ 
TMZ 75 mg/m2/d for 21 days 
q28d 
(TMZ) 
or 
Afatinib 40mg/d (A) 
or 
Afatinib 40mg/d+ TMZ 75 
ErbB, EGFR (A) 
19% (TMZ) 
2.4% (A),  
5% (A+TMZ) 
23% (TMZ) 
3% (A) 
10% (A+TMZ) 
1.9 (TMZ) 
1 (A) 
1.5 (A+TMZ) 
10.6 (TMZ) 
9.8 (A) 
8 (A+TMZ) 
[70] 
mg/m2/d for 21 days q28d 
(A+TMZ) 
Phase II, 
randomized 
1st, n=41 (BEV), 
 n=49 (BEV+VOR) 
RT/TMZ+ 
TMZ 
BEV 10 mg/kg q2wk  
w/o  
VOR 400mg/d for 7 days q2wk 
Histone deacetylase NA NA 
3.6 (BEV), 
4.2 
(BEV+VOR) 
7.0 (BEV), 
8.3 
(BEV+VOR) 
[89] 
Phase II, 
randomized 
1:2 
NA, n=38 (BEV+P), 
 n=83 (BEV+Dasa) NA 
BEV 10 mg/kg q2wk+P 
w/o  
Dasa 100 mg twice/d  
SRC, c-KIT, EPHA2, 
PDGFR (Dasa) 
26.5% 
(BEV+P), 
18.3% 
(BEV+Dasa) 
18.4% 
(BEV+P), 
27.2% 
(BEV+Dasa) 
NA 
7.9  (BEV+P), 
7.2 
(BEV+Dasa) 
[90] 
Abbreviations: A, Afatinib; AAT, antiangiogenic therapy, BEV, bevacizumab; CCNU, lomustine; CED, cediranib; CIL, cilengitide; CSF-1R, Colony stimulating factor 1 receptor, d, day; Dasa: Dasatinib;  EGFR, 
epidermal growth factor receptor; EPHA2, ephrin type-A receptor 2; ErbB, erythroblastic leukemia viral oncogene;, ERL, erlotinib; FGFR, fibroblast growth factor receptor; G: galunisertib; HGF, hepatocyte growth 
factor/scatter factor; c-MET, hepatocyte growth factor receptor; mOS, median overall survival; mPFS, median progression-free survival; mTOR, mammalian target of rapamycin, NA, not available; P, placebo;  PDGF-
R, platelet-derived growth factor receptor; PFS, progression-free survival; PI3K, phosphatidylinositide 3-kinase, PlGF, placental growth factor; pts, patients; q, every; Ref, reference; TMZ, temozolomide; TGFβR1, 
transforming growth factor-β-receptor-1; VEGF, vascular endothelial growth factor VEGFR, receptor to vascular endothelial growth factor; VOR, vorinostat; FLT-3, fms-like tyrosine kinase 3; w/o, with or without; wk, 
week; 
1 Data presented for glioblastoma patients only. In case, the study was designed for different patient populations, only the respective data for glioblastoma patients were included in the table  
2 Reporting of data for glioblastoma patients only was not possible due to lack of reporting data seperately for one study where central histopathology review showed that 6 patients had either anaplastic astrocytoma 
or low-grade glioma [112]  
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Figure 1: Approach for individualized treatment decisions in patients with 
glioblastoma. 
Continuous arrows indicate evidence-based current clinical practice. Dashed arrows 
represent possibilities of individual decision-making which has still to be confirmed.  
Abbreviations: CCNU, lomustine; KPS, Karnofsky performance scale; RT, 
radiotherapy; TMZ, temozolomide; TMZ/RTTMZ, radiotherapy with concomitant 
and maintenance TMZ 
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